Dasatinib, a tyrosine kinase inhibitor, induces YAP phosphorylation, thereby suppressing YAP/TAZ-TEAD target gene expression in renal cell carcinoma [137]. This evidence concerns the gene YAP1 and hereditary clear cell renal cell carcinoma.